YMC – The Future of Gene Therapy Manufacturing: Focus on Innovative Purification Solutions

e-version image

Abstract

In the world of biotechnology and pharmaceutical industry, the effective and reliable purification of complex biomolecules used for gene therapy is of crucial importance. In particular, the isolation of adeno-associated viruses (AAVs), virus-like particles (VLPs), and also plasmid DNA (pDNA) places high demands on the chromatography technologies used. As the demand for gene therapies grows, so does the need for highly specialised solutions which provide the precise purification of native and intact molecules ensuring the safety and efficacy of such therapeutics.


New Targets in the Spotlight: AAVs, VLPs and pDNA

 

In the world of biotechnology and pharmaceutical industry, the effective and reliable purification of complex biomolecules used for gene therapy is of crucial importance. In particular, the isolation of adeno-associated viruses (AAVs), virus-like particles (VLPs), and also plasmid DNA (pDNA) places high demands on the chromatography technologies used. As the demand for gene therapies grows, so does the need for highly specialised solutions which provide the precise purification of native and intact molecules ensuring the safety and efficacy of such therapeutics.

 

Macro-porous IEX Resin – The New Standard in Viral Vector and pDNA Purification

 

Purifying large biomolecules presents distinct challenges. Standard chromatography resins, optimised for proteins, antibodies, and oligonucleotides, often fall short when it comes to viral vectors and plasmid DNA.
Limited pore accessibility and suboptimal binding capacity restrict performance, while the structural similarity of impurities further complicates separation. Macro-porous ...